Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Mobarak S (DISCOVER)
  IRCT20200624047908N		 RCTsofosbuvir and daclatasvirplaceboCOVID 19 hospitalizedsome concern
541/542 inconclusive
  • inconclusive 3 % decrease in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias
Gonzalez (IVER)
  NCT04391127		 RCTivermectinplaceboCOVID 19 hospitalizedsome concern
36/37 inconclusive
    NIH NIAID ACTT-1
          NCT04280705    		 RCTremdesivirplaceboCOVID 19 hospitalizedsome concern
    		541/521 suggested
    • suggested 45 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 29 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 35 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    Kirti
          CTRI/2020/08/027225    		 RCTivermectinplaceboCOVID-19 mild to moderatesome concern
    		57/58 inconclusive
    • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    Shinkai
          JapicCTI-205238    		 RCTfavipiravir placeboCOVID-19 mild to moderatesome concern
    		107/49 safety concern
    • inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    Chaccour
          NCT04390022    		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
    		12/12 inconclusive
    • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias

    COVID-19 severe or critically meta-analysis

    CAP-China (Wang et al.)
          NCT04257656    		 RCTremdesivirplaceboCOVID-19 severe or criticallylow
    		158/79 inconclusive
    • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias
    12 studies excluded by filtering options (10 RCT / 2 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons